查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1557267

全球体外诊断市场 - 2024 年至 2029 年预测

Global In Vitro Diagnostics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 155 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球体外诊断市场预计将从 2024 年的 1,034.15 亿美元增至 2029 年的 1,390.84 亿美元，预测期内复合年增长率为 6.11%。

体外诊断（IVD）市场的成长归因于多种因素，包括感染疾病和持续性疾病日益占主导地位。照护现场诊断的利用率不断提高，以及与体外诊断产品相关的创新技术进步将推动市场成长。提高公众对疾病预防的认识以及采用个人化药物和治疗方法预计将在未来几年扩大该行业。

此外，随着癌症患者的迅速增加，对癌症早期发现和预防的症状治疗和诊断课程的需求将会增加，这将在预测期内发展体外诊断产业。世界卫生组织 (WHO) 于 2024 年 2 月宣布，2022 年全球将新增 2,000 万名癌症病例，到 2025 年将增加 77%，预计将有超过 3,500 万新病例记录。这种扩张是由于人口老化、人口成长以及烟草、酒精、空气污染和肥胖等风险变数的暴露变化所造成的。

推动全球体外诊断市场的因素

  • 慢性病和感染疾病的增加以及人口老化预计将推动市场扩张。

已开发市场和新兴市场老年人口的增加预计将对体外诊断市场做出积极贡献。随着老龄化社会的快速发展，与老龄化相关的疾病的发生率预计将显着增加。全球和其他已开发国家的人口老化正在加剧。例如，日本的劳动人口中老年人比例最高，其次是德国。美国医学会预测，到 2030 年，65 岁及以上的老年人中 60% 将患有多种慢性病。随后，随着老年人口的增加，预计多种疾病将成为全世界的主要疾病。这被认为是体外诊断药物（IVD）市场扩张的关键驱动力。

此外，心血管疾病（CVD）、糖尿病、呼吸系统疾病和癌症等慢性疾病的全球负担正在迅速增加。体外诊断测试透过使用生物标记和检测因生理变化引起的疾病，能够早期诊断和检测这些疾病。慢性病的增加主要是与生活方式相关的一些因素造成的，例如不健康的饮食、吸烟、消费量增加和不活跃的生活方式。

此外，根据国际糖尿病联盟（IDF）2023年11月的最新报告，2021年将有5.37亿成年人（即十分之一）患有糖尿病，到2030年将有6.43亿成年人患有糖尿病，并且预计到 2045 年，人口将增至 7.83 亿。 44% 的成年人（约每 2 人中就有 1 人）仍未被诊断，其中大多数患有第 2 型糖尿病。超过四分之三的糖尿病患者生活在低收入和中等收入国家，5.41 亿成年人可能患有第 2 型糖尿病。此外，医疗机构和政府越来越重视预防措施以遏制慢性病负担的不断增加，也将推动预测期内的市场成长。

全球体外诊断市场的限制因素

  • 不利的赎回可能会阻碍市场成长。

报销不足是体外诊断市场开拓的重大障碍。几年前，美国医疗保险改变了一些体外诊断（包括分子诊断）的报销方式。很少有分子病理学测试没有 HCPCS（医疗保健通用程序编码系统）代码，而是使用未发布的代码申请。在这些情况下，医疗保险行政承包商 (MAC) 为邻近司法管辖区设定分期付款金额。此类变化很可能对美国的分子和基因检测产业产生负面影响，并限制体外诊断市场的扩张。

全球体外诊断市场的地理展望

  • 北美地区预计将占据主要市场占有率。

预计在预测期内，北美将成为最大的体外诊断市场，由于医疗保健框架的发达和患者医疗保健意识的提高，预计该市场将继续保持这一地位。促进新兴市场开拓的其他因素包括设备的可用性、有关其使用的知识的扩展以及大量患有各种慢性病的人的存在。支持体外诊断市场开拓的另一个因素是北美许多大公司的存在。此外，由于医疗支出增加，预计该地区的糖尿病盛行率在预测期内将以最高速度成长。可能的因素，例如大量慢性疾病患者需要 IVD 检测，正在推动该地区的市场扩张。

开拓全球体外诊断的主要市场：

  • 2023 年 5 月，赛默飞世尔科技 (Thermo Fisher Scientific) 和辉瑞 (Pfizer) 同意在 30 多个国家（包括拉丁美洲、非洲、中东和亚洲）扩大对肺癌和乳癌患者进行基于次世代定序(NGS) 的检测的区域范围。该合作伙伴关係旨在将快速 NGS 测试带到更接近患者护理点的分散实验室。 Thermo Fisher 利用其 NGS 技术来检测当地实验室，并确保它们拥有必要的基础设施、训练有素的劳动力和品管措施。同时，辉瑞正在努力为患者提供负担得起的 NGS 检测机会，并提高医疗保健提供者对创新检测的认识。
  • 2023 年 5 月 - 西门子 Healthineers 推出了两款大容量血液学检测系统，消除了血液学检测中的劳动力障碍：Atellica Hema 570 分析仪和 Atellica Hema 580 分析仪。这些分析仪执行全血球计数 (CBC)，这是实验室最常执行的诊断测试之一。它具有连接性、直觉的介面、自动化和基于规则的整合测试，可有效解释复杂的患者结果。这些解决方案可适应大容量血液学测试并确保记录关键资料。
  • 2023 年 5 月 - 女性健康领域的全球领导者 Hologic Inc. 与最近入选的 NFL 角卫 Kelly Ringo 及其母亲、乳癌倖存者 Tralee Hale 合作，呼吁女性提高对重要健康检查重要性的认识。每年一次的乳房X光检查。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章依技术分類的全球体外诊断市场

  • 介绍
  • 免疫检测
  • 分子诊断
  • 血液学
  • 其他的

第六章按应用分列的全球体外诊断市场

  • 介绍
  • 感染疾病
  • 自体免疫疾病
  • 药物测试
  • 肿瘤学
  • 其他的

第七章最终用户的全球体外诊断市场

  • 介绍
  • 诊断实验室
  • 医院和诊所
  • 研究所和研究所

第八章按地区分類的全球体外诊断市场

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Roche Diagnostics
  • Plasmatec
  • Vitro Bio
  • Omega Diagnostics Group PLC & Technologien GmbH
  • DST Diagnostische Systeme
  • SD Biosensor
  • Abbott Diagnostics
  • Meril Diagnostics
  • NIPPON GENE CO., LTD.
  • Rapid Diagnostics Group of Companies
简介目录
Product Code: KSI061611494

The global in-vitro diagnostics market is anticipated to expand at a CAGR of 6.11% throughout the forecast period, from US$103.415 billion in 2024 to a total market value of US$139.084 billion in 2029.

The in vitro diagnostic (IVD) market growth is ascribed to various components, like the rising predominance of infectious and persistent ailments. Rising utilization of point-of-care diagnostics and inventive technological progressions related to in-vitro diagnostics product profiles will surge market growth. Rising awareness among the general population for disease prevention and the adoption of personalized medications and treatment procedures will expand the industry in the coming years.

Additionally, with the fast increment in cancer cases, there will be a rise in the requirement for symptomatic and diagnostic courses for detecting and preventing cancer at an early stage, which can develop the in vitro diagnostics industry in the forecasted period. World Health Organization reported in February 2024 that the number of new cancer cases was 20 million in 2022 worldwide and is predicted to rise by 77% by 2025, with more than 35 million new cases to be recorded. This expansion is credited to population aging, population rise, and changes in exposure to risk variables, such as tobacco, alcohol, air pollution, and obesity.

GLOBAL IN-VITRO DIAGNOSTICS MARKET DRIVER:

  • The increased prevalence of chronic and infectious diseases, as well as an aging population, is expected to boost the market expansion.

The increasing geriatric population in developed and developing countries would positively contribute to the IVD market. The predominance of age-related disorders is anticipated to rise significantly as the world's aging population develops quickly. The aging population is increasing and growing in other industrialized economies globally. Japan, for instance, has the most elevated proportion of the elderly population to the productive population, followed by Germany. The American Medical Association reported that by 2030, it is anticipated that 60% of individuals aged 65 and over will have more than one chronic illness. Subsequently, the worldwide predominance of diverse diseases is expected to grow as the geriatric population increases. This is regarded as a major driver for IVD market expansion.

Additionally, the global burden of chronic diseases like cardiovascular diseases (CVDs), diabetes, respiratory illness, and cancer has been increasing rapidly. In-vitro diagnostic tests will empower the early diagnosis and discovery of these illnesses by using biomarkers and detecting disorders advancement by physiological changes. The rise in chronic illness can be due to numerous components majorly lifestyle-related, like unhealthy diet, use of tobacco, growing alcohol consumption, and inactive life.

In addition, as per the International Diabetes Federation's (IDF) latest report of November 2023, 537 million adults, i.e., 1 in each 10, were living with diabetes in 2021, with the number expected to rise to 643 million by 2030 and 783 million by 2045. 44% of adults stay undiagnosed, which is approximately 1 in 2, with the larger part having type 2 diabetes. Over 3 in 4 diabetes patients live in low and middle-income nations, and 541 million adults have a high chance of developing type 2 diabetes. Moreover, the rising focus of healthcare organizations and governments on preventative measures for controlling the increasing burden of chronic illness will additionally propel market growth in the predicted period.

GLOBAL IN-VITRO DIAGNOSTICS MARKET RESTRAINT:

  • Unfavorable reimbursement can hinder the market growth.

Inadequate reimbursement is a substantial barrier to the IVD market development. A couple of years ago, Medicare in the US changed how it repaid several IVD tests, including molecular diagnostics. Few molecular pathology tests do not have their claim Healthcare Common Procedure Coding System (HCPCS) codes, so they are charged utilizing unlisted codes instead. Medicare Administrative Contractors (MACs) set an installment sum for their nearby purviews on such occasions. These changes will likely harm the molecular and hereditary testing industry within the United States, constraining the IVD market's expansion.

Global In-Vitro Diagnostics Market Geographical Outlook

  • The North American region is expected to hold a substantial market share.

North America is anticipated to be the biggest market for in vitro diagnostics amid the projected period, and it is likely to proceed to do so due to its well-developed healthcare framework and rising healthcare mindfulness among patients. Other components that contribute to the market's development include the availability of devices, expanded knowledge about their utilization, and the presence of many populations suffering from diverse chronic conditions. Another component driving the in vitro diagnostics market development is the presence of many major companies in North America. Moreover, due to an increase in healthcare expenditure, the rate of diabetes in the region is expected to extend at the highest rate throughout the projection period. Conceivable factors, such as the huge populace of patients with other chronic illnesses that necessitate IVD testing, are fueling the regional market's expansion.

Global In-Vitro Diagnostics Key Market Developments:

  • May 2023- Thermo Fisher Scientific and Pfizer agreed to expand local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries, including Latin America, Africa, the Middle East, and Asia. The collaboration aims to bring rapid NGS testing to decentralized labs closer to patients' treatment sites. Thermo Fisher works by detecting local labs by employing its NGS technology, ensuring they have the required infrastructure, trained workforce, and quality control measures. At the same time, Pfizer operates to provide affordable patient access to NGS tests and increase healthcare providers' awareness of innovative testing.
  • May 2023- Siemens Healthineers introduced two high-volume hematology test systems, the Atellica Hema 570 Analyzer and the Atellica Hema 580 Analyzer, which clear out labor barriers in hematology testing. These analyzers execute complete blood counts (CBC), among the most performed diagnostic tests in laboratories. They provide connectivity, intuitive interfaces, automation, and integrated rules-based testing to interpret complex patient results efficiently. These solutions address the requirement for high-volume hematology testing and deliver critical data reliably.
  • May 2023- Hologic Inc., a global leader in women's health, announced a collaboration with NFL cornerback Kelee Ringo, who was drafted recently, and his mother Tralee Hale, a breast cancer survivor, to raise awareness among women about the importance of making yearly mammograms and other critical health screenings a primacy.

Market Segmentation:

The Global In-Vitro Diagnostics market is segmented and analyzed as below:

By Technique

  • Immunoassay
  • Molecular Diagnostics
  • Hematology
  • Others

By Application

  • Infectious diseases
  • Autoimmune diseases
  • Drug Testing
  • Oncology
  • Others

By End-User

  • Diagnostic Laboratories
  • Hospitals and Clinics
  • Research Laboratories and Institutes

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNIQUE

  • 5.1. Introduction
  • 5.2. Immunoassay
  • 5.3. Molecular Diagnostics
  • 5.4. Hematology
  • 5.5. Others

6. GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Infectious diseases
  • 6.3. Autoimmune diseases
  • 6.4. Drug Testing
  • 6.5. Oncology
  • 6.6. Others

7. GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
  • 7.3. Hospitals and Clinics
  • 7.4. Research Laboratories and Institutes

8. GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Technique
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Technique
    • 8.3.2. By Application
    • 8.3.3. By End User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Technique
    • 8.4.2. By Application
    • 8.4.3. By End User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. France
      • 8.4.4.3. United Kingdom
      • 8.4.4.4. Italy
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Technique
    • 8.5.2. By Application
    • 8.5.3. By End User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Israel
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Technique
    • 8.6.2. By Application
    • 8.6.3. By End User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. South Korea
      • 8.6.4.4. India
      • 8.6.4.5. Australia
      • 8.6.4.6. Taiwan
      • 8.6.4.7. Thailand
      • 8.6.4.8. Indonesia
      • 8.6.4.9. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Roche Diagnostics
  • 10.2. Plasmatec
  • 10.3. Vitro Bio
  • 10.4. Omega Diagnostics Group PLC & Technologien GmbH
  • 10.5. DST Diagnostische Systeme
  • 10.6. SD Biosensor
  • 10.7. Abbott Diagnostics
  • 10.8. Meril Diagnostics
  • 10.9. NIPPON GENE CO., LTD.
  • 10.10. Rapid Diagnostics Group of Companies